U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSIGLITAZONE

SMILES

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3

InChI

InChIKey=YASAKCUCGLMORW-UHFFFAOYSA-N
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

HIDE SMILES / InChI
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/rosiglitazone.html http://www.rxlist.com/avandia-drug.htm http://www.wikidoc.org/index.php/Rosiglitazone

Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.

CNS Activity

Originator

Approval Year

1999
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 40.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
AVANDIA

Approved Use

After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS®) or pioglitazone-containing products (ACTOPLUS MET®, ACTOPLUS MET XR®, DUETACT®) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
432 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
598 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2890 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
2971 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.59 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.37 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
DLT: Headache, Malaise...
Disc. AE: Pain in leg...
Dose limiting toxicities:
Headache (3.1%)
Malaise (3.1%)
Oedema legs (9.4%)
AEs leading to
discontinuation/dose reduction:
Pain in leg (3.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
Disc. AE: Macular edema...
AEs leading to
discontinuation/dose reduction:
Macular edema
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Disc. AE: Congestive heart failure, Myocardial ischemia...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Myocardial ischemia (2%)
Fluid retention
Edema
Weight gain
Anemia
Macular edema
Fracture bone
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Headache 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Malaise 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Pain in leg 3.1%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Oedema legs 9.4%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Macular edema Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
Myocardial ischemia 2%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Anemia Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Congestive heart failure Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Fluid retention Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Fracture bone Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Macular edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Weight gain Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
PubMed

PubMed

TitleDatePubMed
Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
1999 Jul
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
1999 Jun
Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.
2000 May
Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
2002 Apr
Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.
2002 Jan
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
2002 Jan 11
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
2002 Jul
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
2002 May
Rosiglitazone-induced granulomatous hepatitis.
2002 May-Jun
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
2003 Apr
Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
2003 Aug 15
Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.
2003 Dec
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
2003 Jan
Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes.
2003 Jan 3
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.
2003 Oct
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
2004 Dec
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
2004 Jan 1
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.
2004 Jul 1
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.
2004 May 15
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
2004 Oct
Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
2004 Oct
The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes.
2005
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.
2005 Feb
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
2005 Jan
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.
2005 Jun
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
2005 Mar
Fatty acids and expression of adipokines.
2005 May 30
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.
2005 Oct
Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.
2005 Sep
Patents

Patents

06515132
8
JP2002543077A
8
JP2004536047A
24
JP2008195625A
8
JP2011252007A
8
JP4365554B2
22
JP4741458B2
8

Sample Use Guides

In Vivo Use Guide
Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Rosiglitazone treatment (5 uM) prevents NO and prostacyclin overproduction by inhibiting microparticles-induced iNOS and COX-2 expression.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:18:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:18:29 GMT 2023
Record UNII
05V02F2KDG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROSIGLITAZONE
EMA EPAR   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
ROSIGLIZOLE
Brand Name English
BRL-49653
Code English
NSC-758698
Code English
ROSIGLITAZONE [MI]
Common Name English
rosiglitazone [INN]
Common Name English
ROSIGLITAZONE [EMA EPAR]
Common Name English
REZULT
Brand Name English
TDZ-01
Code English
ROSIGLITAZONE [VANDF]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-
Systematic Name English
ROSIGLITAZONE [MART.]
Common Name English
ROSIGLITAZONE [IARC]
Common Name English
ROSVEL
Brand Name English
GAUDIL
Brand Name English
5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
ROSIGLITAZONE [HSDB]
Common Name English
Rosiglitazone [WHO-DD]
Common Name English
5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000011272
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-ATC A10BD03
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
LIVERTOX NBK548114
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000180190
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-ATC A10BD04
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-VATC QA10BG02
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000175374
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NCI_THESAURUS C1934
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-VATC QA10BD04
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-ATC A10BG02
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000170119
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000011272
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
WHO-VATC QA10BD03
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000180186
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000170119
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
NDF-RT N0000011272
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
Code System Code Type Description
SMS_ID
100000089168
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
EVMPD
SUB10388MIG
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
DRUG CENTRAL
2405
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
INN
7662
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
PUBCHEM
77999
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
HSDB
7555
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
DRUG BANK
DB00412
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
NSC
758698
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
LACTMED
Rosiglitazone
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
WIKIPEDIA
ROSIGLITAZONE
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
IUPHAR
1056
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
DAILYMED
05V02F2KDG
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
CHEBI
50122
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
MESH
C089730
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
NCI_THESAURUS
C62076
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID7037131
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
MERCK INDEX
m9666
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY Merck Index
CAS
122320-73-4
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL121
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
FDA UNII
05V02F2KDG
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY
RXCUI
84108
Created by admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
PRIMARY RxNorm
Related Record Type Details
OCT-1
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET -> INHIBITOR
Binding Assay
IC50
Structure of ROSIGLITAZONE POTASSIUM
SALT/SOLVATE -> PARENT
OATP-8
TRANSPORTER -> INHIBITOR
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (S)-
ENANTIOMER -> RACEMATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of Rosiglitazone tartrate
SALT/SOLVATE -> PARENT
OATP-B
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
Structure of ROSIGLITAZONE SODIUM
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE FUMARATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE CHOLINATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (R)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of N-DESMETHYL-O-HYDROXY ROSIGLITAZONE
METABOLITE INACTIVE -> PARENT
MINOR
Structure of P-HYDROXY ROSIGLITAZONE
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
Structure of ROSIGLITAZONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966